Transcend Therapeutics
Tuesday, June 04, 2024
Company Presentation
![CNS/Neurological](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 1
Transcend Therapeutics, founded in 2021, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric disease. Transcend is developing TSND-201 (methylone), a rapid-acting neuroplastogen, as a treatment for post-traumatic stress disorder (PTSD) and other CNS indications. Transcend recently presented positive interim Phase 2a in patients with PTSD, which demonstrated rapid, robust, and durable therapeutic effects in PTSD and a signal for rapid, robust, and durable improvements in depressive symptoms. Transcend’s leadership team has made pivotal contributions to 13 successful NDAs (including recent MDD approval), $3.5B in M&A, and significant public company value creation.
![Transcend Therapeutics](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1806707-1-JPG(1).png)
Company Website:
https://www.transcendtherapeutics.com
Lead Product in Development:
TSND-201
Company HQ City
New York
Company HQ State
NY
Company HQ Country
United States
CEO/Top Company Official
Blake Mandell
Development Phase of Primary Product
Phase II
Primary Speaker